Brexit Won’t Alter EU Agency Heads’ Ambitious Work Plan – For Now
Executive Summary
Europe’s medicines agency heads say they are pressing on as planned with the priorities and activities in the joint “strategy to 2020” they have with the European Medicines Agency. But this could change and, in any case, more resources are needed and agencies need to engage more to support delivery of their plan.
You may also be interested in...
Brexit Likely To Force ‘Refocusing’ Of Ambitious EU Network Strategy
The European Medicines Agency and drug regulators throughout the EU are having to invest huge amounts of time and effort in dealing with the fall-out from Brexit - and it hasn't even happened yet. Plans for working together on bigger issues agreed on a few years ago will likely have to change, senior regulator Thomas Senderovitz tells the Pink Sheet.
EU Regulators Urge Pharma To Share Their Brexit Plans
Sponsors of medicines evaluated through the EU's decentralized procedure are being urged to share their plans regarding Brexit with national agencies as soon as possible to help with planning. The head of the Dutch Medicines Agency thinks that the human medicines sector can learn from the progress being made in the veterinary space on this front.
Tweeting The News: First Takes From EU Regulatory Conferences
The Pink Sheet’s London-based staff have been busy this week covering regulatory affairs conferences… and tweeting while they were there.